ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.

Author: Yojind Vubar
Country: Botswana
Language: English (Spanish)
Genre: Environment
Published (Last): 25 November 2017
Pages: 273
PDF File Size: 15.59 Mb
ePub File Size: 11.80 Mb
ISBN: 986-3-54505-708-3
Downloads: 19236
Price: Free* [*Free Regsitration Required]
Uploader: Bralmaran

J Clin Pharm Pract ; 3: Underrepresentation 1954 patients 65 years of age or older in cancer-treatment trials. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: All others were randomized to either observation or topotecan 1. The greatest part of the evidence analysed in the meeting comes from small sub-groups of patients with PS2, enrolled in clinical trials usually including patients with a PS ranging from 0 to 2.

Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review

Effects of vinorelbine on eocg of life and survival of elderly patients with advanced non small cell lung cancer. Study Design and Results The study by Noda et al. In fact, it has been argued by some that the therapeutic index in advanced disease is too narrow to warrant subjecting ecoy to the unpleasant side effects of treatment [ 24 ].

PS2 may be due to tumour-related symptoms e. Cancer Res ; All these observations, as underlined by the authors, reinforce the perception that PS2 patients eco special consideration when receiving chemotherapy. These are important studies to compare because they were conducted at nearly the same time and in very similar though not identical patient populations.


As in clinical research focused on elderly patients, in order to avoid selection bias, evidence should be based on clinical trials dedicated to these patients rather than on sub-group analysis coming from non-specifically designed trials [ 47 ]. Selected toxicities from ECOG Clin Cancer Res ; 5: PS2 patients reported the worst scores at baseline assessment.

There was an imbalance by sex 159 more men being in the CP-alone arm.

Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer. High priority should be given to eccog evaluation of tolerability and efficacy of platinum-based combinations, and to the testing of new biological agents. There were no between-group differences in grade 3 or 4 neutropenia, thrombocytopenia, or infection.

Google Scholar Articles by Lynch, T. There were three deaths on study on the irinotecan arm and one death on the etoposide arm. Patients were eligible only if they had received no prior chemotherapy. However, the benefit achievable seems more evident for fit patients PS0 or -1 and there is no consistent evidence about the real efficacy of platinum-based treatment for PS2 patients [ 1315 ].

Randomized wcog of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. According to disease-related symptoms and pre-existing co-morbidities, patients could be divided in different sub-groups, with the aim of properly predicting risks and benefits of different therapeutic approaches.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

The data with four cycles in these two most recently completed studies are remarkably similar to data using six cycles of therapy, leading Dr. Lung Cancer ; 38 suppl 3: With the aims of reviewing the evidence supporting each of these therapeutic options, possibly reaching a consensus for treatment of PS2 patients affected by advanced Scog in clinical practice, and suggesting the priorities for clinical research in this field, an European Experts Panel took place in Avellino, Italy in April A first point of discussion was the evidence supporting the role of chemotherapy itself in PS2 patients.


Enrollment required a PS score of 0 or 1. In this window In a new window.

Preliminary results in the supportive care setting. Citing articles via Web of Science A Review James R. This raises the question of whether time to progression will ultimately become the most important measure in NSCLC trials rather than survival.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

The study enrolled patients with a PS of between 0 and 2. No significant interaction between treatment and PS in terms of overall ecg is described, and platinum-free combination chemotherapy could represent a reasonable, less toxic option for PS2 patients.

Lung cancer mortality in European regions — Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.